Participants receiving an isolated abdominal wall transplant will be treated with immunosuppression known to prevent rejection of allografted tissues and designed to minimize exposure to calcineurin inhibitor based immunosuppression by using a drug called Belatacept. This will include monthly infusions for the 18-month study period that will take place at Duke University Medical Center.